Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug - Regeneron Pharmaceuticals (NASDAQ:REGN

Regeneron's Pasatru scores FDA approval in ultrarare bone lesions disorder

After more than 10 years in development, Regeneron secured a landmark approval for its monoclonal antibody garetosmab, now commercially known as Pasatru. | Regeneron's Pasatru has crossed the finish line with an FDA…